Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The news that USPTO director Kathi Vidal is to step down early and WIPO’s aims for a design law treaty were among the biggest IP talking points this week
David Parrish expects AI to be among the major talking points for a newly formed committee aimed at protecting the interests of London-based IP practitioners, firms, and their clients